Facebook
Twitter
LinkedIn
ForwardCMHC Masterclass CME Symposium Information
Return to Main Meeting Accreditation Page
CME SYMPOSIUM ACTIVITY TITLE
Assessing the Evolving Role of TAVR Across the Risk Continuum: Emerging Evidence, Evolving Guidance, and Expert Perspectives
ACTIVITY DATE
January 29, 2022 | 1:00 PM - 2:00 PM |CMHC Masterclass | Eastern Time
EDUCATIONAL SUPPORT
This activity is supported in part by educational grants from Medtronic and Edwards Lifesciences LLC.
TARGET AUDIENCE
US-based healthcare professionals, including primary care clinicians (PCPs), interventional cardiologists, cardiologists, registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals.
PROGRAM OVERVIEW
AS is a fatal disease if not treated promptly, especially in the older population. There is a need of multidisciplinary team approach for the comprehensive diagnosis, staging, risk stratification and treatment involving patient preferences, in order to optimize the management of this insidious disease. Studies have suggested that TAVR can be used as an alternative for SVAR in high risk as well as low risk patients with severe AS. Additionally, guidelines have underlined the benefits of TAVR with many terms and conditions. The choice of intervention for a patient with severe AS should be a shared decision making process that involves the lifetime benefits as well as risk associated with the therapy. This educational activity will help clinicians not only with screening and staging based on updated guidelines, but with choosing the best treatment option in this setting.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
• Determine the prevalence and clinical significance of severe aortic stenosis.
• Outline strategies to screen, diagnose, and risk stratify patients with aortic stenosis as a means to identify patient candidates who may benefit from TAVR treatment.
• Summarize the updated guidelines and evidence from recent clinical trials and real-world studies of TAVR vs. SAVR in AS patients across the risk continuum
• Develop individualized treatment plans for patients with severe aortic stenosis based on updated evidence, guidelines, and patient-specific clinical presentation and needs
FACULTY
Deepak L. Bhatt, MD, MPH (Chair)
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart and Vascular Center
Professor of Medicine, Harvard Medical School
Boston, MA
Angela Lowenstern, MD, MHSc
Assistant Professor of Medicine
Interventional Cardiology
Vanderbilt University Medical Center
Nashville, TN
Gilbert H. Tang, MD, MSc, MBA, FACC, FSCAI
Associate Professor of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai
Surgical Director, Structural Heart Program, Mount Sinai Health System
New York, NY
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is a knowledged-based activity. Universal Activity Numbers (UAN) JA4008162-0000-22-036-L01-P.
For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor within 4-6 weeks. Pharmacists have up to thirty (30) days from the live event to complete the evaluation and claim credit.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CONTINUING DIETICIAN EDUCATION
This program offers 1.0 CPEUs for dieticians.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.
Faculty
A full listing of faculty disclosures will be provided here.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
REQUEST FOR CREDIT
This information is coming soon.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no registration fee for participating and receiving CME/CE credit for this educational activity.
Return to Main Meeting Accreditation Page